Biotia Secures $9 Million to Revolutionize Infectious Disease Diagnostics
October 7, 2026, 3:32 pm
Biotia raised $9 million in oversubscribed financing. The health tech leader advances infectious disease diagnostics. Its BIOTIA-ID Urine Test revolutionizes recurrent and complicated UTI diagnosis. The test uses clinical metagenomics and AI. It delivers 97% sensitivity and 99% specificity. This Cornell Tech spinout secured $19.4 million total funding. Biotia targets market expansion. Women's health and orthopedic infections are key areas. This innovation provides rapid, precise pathogen identification, tackling antibiotic resistance head-on.
Biotia, a cutting-edge health technology company, announced a significant funding round. It secured an oversubscribed $9 million in financing. This infusion of capital fuels its mission. Biotia develops advanced infectious disease diagnostics. The funding round brings Biotia's total capital raised to $19.4 million. It marks a major milestone for the company.
A diverse group of investors participated. Convergent Ventures, DigitalDx Ventures, and Cloquet Capital Partners joined. Continuum Health Ventures, I-Lab Angels, and EGB Capital also contributed. Leawood Venture Capital, Red Bear Angels, and Red Bear Ventures provided backing. Notably, the family offices of Tim Barry and Dr. Clive Fields invested. Barry and Fields are co-founders of VillageMD. This broad investor base signals strong confidence. It validates Biotia’s technology and market approach.
Urinary Tract Infections (UTIs) represent a massive healthcare burden. They account for 10.5 million office visits annually in the U.S. Another 3 million emergency department encounters occur. UTIs lead to 400,000 hospitalizations each year. The estimated annual cost exceeds $4.8 billion. Standard diagnostic methods often fall short. Traditional urine cultures detect only fast-growing bacteria. This limitation leaves many patients undiagnosed. It leads to persistent symptoms and repeated antibiotic courses. Such practices fuel antibiotic resistance, a global health crisis. Patients with recurrent UTIs, catheters, or negative culture results suffer. They cycle through ineffective treatments. Biotia addresses this critical diagnostic gap.
Biotia leverages clinical metagenomics. This advanced technology employs next-generation sequencing. It directly reads pathogen DNA from a sample. This method bypasses the need for bacterial growth in culture. The flagship product is the BIOTIA-ID Urine Test. It identifies the cause of recurrent and complicated UTIs. Its performance is exceptional. The test boasts 97% sensitivity and 99% specificity. It detects 44 urogenital pathogens. It also identifies 16 drug resistance markers. This comprehensive insight guides targeted treatment. It minimizes empiric antibiotic prescriptions. Results are typically available within 2 to 3 business days.
Biotia operates its own high-complexity diagnostic laboratory. This CLIA-certified facility is located in New York City. It is also New York State–approved. The lab infrastructure supports rapid and accurate testing. Patients across all 50 U.S. states can access the BIOTIA-ID Urine Test. Clinicians can order tests for their patients. Biotia also offers a consumer-initiated testing service. Patients receive an at-home collection kit. Telehealth partner Clinova Solutions provides expert review. UTI specialists offer care guidance. This multi-channel access improves patient outcomes. It offers precise answers instead of repeated prescriptions.
The market for Biotia’s solutions is substantial. UTIs affect over 150 million people worldwide each year. Recurrent UTIs impact 14.5% to 40% of women. Complicated UTIs, often catheter-associated, account for 1 million U.S. cases annually. These are the high-risk, hard-to-treat patients. Standard culture fails them. Sequencing-based diagnostics offer significant value here. Biotia’s platform extends beyond UTIs. It addresses other major infectious disease markets.
Biotia plans strategic expansion. The company is developing new diagnostic panels. A women’s health panel is in the pipeline. It covers sexually transmitted infections (STIs) and vaginal health. The global STD diagnostics market is large. It was valued at $11.2 billion in 2023. Projections suggest growth to $21.74 billion by 2032. Biotia also collaborates with Hospital for Special Surgery (HSS). They are developing a joint fluid test. This targets orthopedic infections, another critical area.
Biotia’s business model is robust. It relies on a proprietary platform. This platform pairs next-generation sequencing with AI-driven bioinformatics. New assays leverage existing lab infrastructure. This reduces marginal costs. Revenue streams are diverse. Clinicians order tests for complicated and recurrent UTIs. Consumer-initiated testing provides direct patient access. B2B partnerships target women's health companies, employers, and health systems. Biotia is actively pursuing insurance coverage for its tests. This will further reduce patient out-of-pocket costs.
The company emerged from Cornell Tech. Cofounders Niamh O’Hara (CEO) and Dr. Chris Mason established Biotia. Their personal experiences with undiagnosed infections inspired their work. They questioned why powerful genomic tools remained largely in research. Biotia differentiates itself through innovation. Years of R&D produced patented lab protocols. Extensive pathogen databases were built. Advanced analytic software was developed. Biotia prioritizes diagnostic and antimicrobial stewardship. Patients are carefully screened. This ensures the right test for the right patient. It reduces the risk of overdiagnosis. It mitigates inappropriate antimicrobial use. Biotia is not a "wellness brand." It focuses on rigorous clinical utility.
Strategic growth remains paramount. Biotia plans to scale its team. It seeks New York State CLEP approval for additional sample types. Progress on insurance coverage for its assays is a key goal. Major partnerships are going live. These leverage recent laboratory expansions. Biotia also launches additional clinical studies. These assess test impact on patient health outcomes. The company remains judicious with capital expenditure. It ensures long-term runway and sustainability. Biotia aims to deliver precise, rapid infectious disease solutions globally.
Biotia, a cutting-edge health technology company, announced a significant funding round. It secured an oversubscribed $9 million in financing. This infusion of capital fuels its mission. Biotia develops advanced infectious disease diagnostics. The funding round brings Biotia's total capital raised to $19.4 million. It marks a major milestone for the company.
A diverse group of investors participated. Convergent Ventures, DigitalDx Ventures, and Cloquet Capital Partners joined. Continuum Health Ventures, I-Lab Angels, and EGB Capital also contributed. Leawood Venture Capital, Red Bear Angels, and Red Bear Ventures provided backing. Notably, the family offices of Tim Barry and Dr. Clive Fields invested. Barry and Fields are co-founders of VillageMD. This broad investor base signals strong confidence. It validates Biotia’s technology and market approach.
Urinary Tract Infections (UTIs) represent a massive healthcare burden. They account for 10.5 million office visits annually in the U.S. Another 3 million emergency department encounters occur. UTIs lead to 400,000 hospitalizations each year. The estimated annual cost exceeds $4.8 billion. Standard diagnostic methods often fall short. Traditional urine cultures detect only fast-growing bacteria. This limitation leaves many patients undiagnosed. It leads to persistent symptoms and repeated antibiotic courses. Such practices fuel antibiotic resistance, a global health crisis. Patients with recurrent UTIs, catheters, or negative culture results suffer. They cycle through ineffective treatments. Biotia addresses this critical diagnostic gap.
Biotia leverages clinical metagenomics. This advanced technology employs next-generation sequencing. It directly reads pathogen DNA from a sample. This method bypasses the need for bacterial growth in culture. The flagship product is the BIOTIA-ID Urine Test. It identifies the cause of recurrent and complicated UTIs. Its performance is exceptional. The test boasts 97% sensitivity and 99% specificity. It detects 44 urogenital pathogens. It also identifies 16 drug resistance markers. This comprehensive insight guides targeted treatment. It minimizes empiric antibiotic prescriptions. Results are typically available within 2 to 3 business days.
Biotia operates its own high-complexity diagnostic laboratory. This CLIA-certified facility is located in New York City. It is also New York State–approved. The lab infrastructure supports rapid and accurate testing. Patients across all 50 U.S. states can access the BIOTIA-ID Urine Test. Clinicians can order tests for their patients. Biotia also offers a consumer-initiated testing service. Patients receive an at-home collection kit. Telehealth partner Clinova Solutions provides expert review. UTI specialists offer care guidance. This multi-channel access improves patient outcomes. It offers precise answers instead of repeated prescriptions.
The market for Biotia’s solutions is substantial. UTIs affect over 150 million people worldwide each year. Recurrent UTIs impact 14.5% to 40% of women. Complicated UTIs, often catheter-associated, account for 1 million U.S. cases annually. These are the high-risk, hard-to-treat patients. Standard culture fails them. Sequencing-based diagnostics offer significant value here. Biotia’s platform extends beyond UTIs. It addresses other major infectious disease markets.
Biotia plans strategic expansion. The company is developing new diagnostic panels. A women’s health panel is in the pipeline. It covers sexually transmitted infections (STIs) and vaginal health. The global STD diagnostics market is large. It was valued at $11.2 billion in 2023. Projections suggest growth to $21.74 billion by 2032. Biotia also collaborates with Hospital for Special Surgery (HSS). They are developing a joint fluid test. This targets orthopedic infections, another critical area.
Biotia’s business model is robust. It relies on a proprietary platform. This platform pairs next-generation sequencing with AI-driven bioinformatics. New assays leverage existing lab infrastructure. This reduces marginal costs. Revenue streams are diverse. Clinicians order tests for complicated and recurrent UTIs. Consumer-initiated testing provides direct patient access. B2B partnerships target women's health companies, employers, and health systems. Biotia is actively pursuing insurance coverage for its tests. This will further reduce patient out-of-pocket costs.
The company emerged from Cornell Tech. Cofounders Niamh O’Hara (CEO) and Dr. Chris Mason established Biotia. Their personal experiences with undiagnosed infections inspired their work. They questioned why powerful genomic tools remained largely in research. Biotia differentiates itself through innovation. Years of R&D produced patented lab protocols. Extensive pathogen databases were built. Advanced analytic software was developed. Biotia prioritizes diagnostic and antimicrobial stewardship. Patients are carefully screened. This ensures the right test for the right patient. It reduces the risk of overdiagnosis. It mitigates inappropriate antimicrobial use. Biotia is not a "wellness brand." It focuses on rigorous clinical utility.
Strategic growth remains paramount. Biotia plans to scale its team. It seeks New York State CLEP approval for additional sample types. Progress on insurance coverage for its assays is a key goal. Major partnerships are going live. These leverage recent laboratory expansions. Biotia also launches additional clinical studies. These assess test impact on patient health outcomes. The company remains judicious with capital expenditure. It ensures long-term runway and sustainability. Biotia aims to deliver precise, rapid infectious disease solutions globally.